RBMS1 and Hepatic fibrosis: Xiao et al indicated that YC-1 derivatives might be potential agents for hepatic fibrosis therapy through suppressing activated LX-2 cell, a human HSC cell viability and inducing cell apoptosis [17].Therefore, it is likely that YC-1 decreased ɑ-SMA and extracellular matrix accumulation in livers may through the inhibition of HSCs via multiple mechanisms.